Contact Us
Drug Search Results
More Filters [+]

PF-04937319

Alternative Names: pf-04937319, pf04937319, pf 04937319
Latest Update: 2023-12-01
Latest Update Note: PubMed Publication

Product Description

a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes (Sourced from: https://pubmed.ncbi.nlm.nih.gov/25885172/)

Mechanisms of Action: GK Activator

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for PF-04937319

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Type 2 Diabetes

Phase 1: Type 2 Diabetes|Overweight|Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
JapicCTI-142719

P1

Unknown

Type 2 Diabetes

2015-03-01

B1621018

P1

Completed

Type 2 Diabetes

2015-03-01

B1621015

P1

Completed

Type 2 Diabetes

2015-01-01

B1621019

P1

Completed

Type 2 Diabetes

2014-03-01

Recent News Events

Date

Type

Title

12/01/2023

PubMed

 Empirical scaling factor for predicting human pharmacokinetic profiles of disproportionate metabolites using the Css-MRTpo method and chimeric mice with humanised livers.

07/01/2020

PubMed

 A novel Css-MRTpo approach to simulate oral plasma concentration-time profiles of the partial glucokinase activator PF-04937319 and its disproportionate N-demethylated metabolite in humans using chimeric mice with humanized livers.

01/20/2020

News Article

 Glucokinase - Pipeline Review, H2 2019 - ResearchAndMarkets.com

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions